Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
December 13, 2021updated 07 Jan 2022 6:47am

The majority of glaucoma cases remain undiagnosed in the US

The prevalence of glaucoma in the US is expected to increase in the near future due to the country’s growing ageing population.

By GlobalData Healthcare

Glaucoma is one of the leading causes of blindness in the US, especially in elderly people. It is a common, asymptomatic group of eye diseases that causes damage to the eye’s optic nerve, resulting in progressive, irreversible vision loss. As the disease is asymptomatic in the earlier stages and progresses slowly, most cases of the condition go undiagnosed. The burden of glaucoma is expected to increase in the near future due to the growing ageing population, especially if the diagnosis rate continues to remain low.

Primary open-angle glaucoma (POAG) represents almost 90% of glaucoma cases. GlobalData epidemiologists forecast that the total prevalent cases (diagnosed and undiagnosed) of POAG in the US will grow at an annual growth rate (AGR) of 2.8% a year over the next ten years, from around 3.6 million cases last year to 4.6 million cases in 2030 (Figure 1). The diagnosed prevalent cases, however, represent less than half of the total cases, with around 1.6 million diagnosed prevalent cases last year and two million diagnosed prevalent cases in 2030. Various studies in the US have reported the diagnosis rate of glaucoma to represent 30–50% of the total cases.

According to a February 2016 study conducted by Gupta and colleagues and published in the Investigative Ophthalmology and Visual Science journal, around 43.7% of cases in the survey had a previous physician diagnosis of glaucoma. The study used data from the 2005–08 National Health and Nutrition Examination Survey, a nationally representative survey of the US population. The burden of undiagnosed and untreated cases was also shared unevenly in the US population. Undiagnosed glaucoma cases were higher in African Americans compared to the White population, while undiagnosed and untreated cases were also higher in the lower socioeconomic group. In addition, comorbid conditions such as diabetes and high blood pressure were found to be major factors that increased the risk and complications of glaucoma. In the US, diabetes and high blood pressure are widely prevalent and predicted to rise further in the next few years. As such, GlobalData epidemiologists believe that the number of glaucoma cases will continue to rise, and the share of undiagnosed cases is unlikely to decrease in the near future.

Glaucoma is a debilitating condition in terms of quality-of-life impact and both progressive and irreversible deterioration in vision. When diagnosed early, however, the condition is manageable and prevents further deterioration of vision. Regular screening is needed, especially in adults aged 40 years and older, to detect the signs of glaucoma earlier. Tailoring the public health policy for early diagnosis and treatment to the high-risk population will help lessen the burden of this condition.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU